Palisade: Initiating 'Buy' On PALI-2108 UC Study Start And Differentiated PDE4 Inhibitor
Palisade Bio Inc PALI
$1.16
▼ -2.52%
($-0.03)
⬇️ Below Yest. Low
Open
$1.18
Prev Close
$1.19
Day Range
$1.13 – $1.20
52W Range
$1.08 – $2.86
Market Cap
$207.38M
Beta
1.65
EPS (TTM)
$-0.64
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2006-12-20 |
| Shares Out. | 174,270,000 |
| Website | palisadebio.com/ ↗ |
| Phone | 13026974590 |
| Employees | 14 |
| Revenue | $500,000 |
| Gross Profit | $500,000 |
| Net Income | -$10.6M |
| Free Cash Flow | -$18.2M |
| Total Assets | $127.3M |
| Total Liabilities | $5.6M |
| Equity | $121.7M |
About Palisade Bio Inc
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Palisade Bio Inc is a publicly traded company under the ticker symbol PALI on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
17 analysts (2026-11-01)
📰 Latest News for PALI
Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis
Palisade Bio Doses First Patient In Its ASCENTRA-UC Phase 2b Clinical Trial Evaluating PALI-2108 In ~204 Patients With Moderately To Severely Active Ulcerative Colitis; 12-Week Topline Results Expected In Q4 2027